Sinovac Biotech Ltd (SVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,156,429 | 602,217 | 1,129,122 | 4,286,377 | 11,619,760 |
| Marketable Securities | 5,483,073 | 9,613,328 | 9,894,575 | 7,034,569 | 1,806,449 |
| Receivables | 313,087 | 316,329 | 424,945 | 609,489 | 952,402 |
| Inventories | 94,309 | 96,920 | 135,609 | 180,719 | 375,511 |
| Other current assets | 0 | -5 | 1 | 4 | 1 |
| TOTAL | $7,064,498 | $10,644,510 | $11,597,300 | $12,126,400 | $14,915,110 |
| Non-Current Assets | |||||
| PPE Net | 706,059 | 880,968 | 951,978 | 993,781 | 903,298 |
| Investments And Advances | 512,324 | 491,349 | 879,842 | 661,440 | 655,835 |
| Intangibles | 90,283 | 150,087 | 8,520 | 9,699 | 1,480 |
| Other Non-Current Assets | 168,561 | 170,362 | 174,381 | 323,252 | 272,452 |
| TOTAL | $1,477,227 | $1,692,766 | $2,014,721 | $1,988,172 | $1,833,065 |
| Total Assets | $8,541,725 | $12,337,280 | $13,612,020 | $14,114,570 | $16,748,170 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 229,374 | 211,919 | 76,089 | 293 | 3,099 |
| Accounts payable and accrued liabilities | 606,030 | 802,996 | 989,245 | 905,923 | 1,020,651 |
| Other current liabilities | 3,035 | 1,728 | 1,586 | 15,120 | 12,559 |
| TOTAL | $1,540,365 | $1,451,898 | $1,292,712 | $1,091,635 | $2,412,846 |
| Non-Current Liabilities | |||||
| Long Term Debt | 265,484 | 163,840 | 177,817 | 11,513 | 17,376 |
| Deferred Revenues | 11,265 | 12,211 | 27,049 | 17,955 | 79,941 |
| Other Non-Current Liabilities | 153,712 | 68,313 | 152,264 | 82,968 | -5,873,652 |
| TOTAL | $605,108 | $591,953 | $676,833 | $310,272 | $459,319 |
| Total Liabilities | $2,145,473 | $2,043,851 | $1,969,545 | $1,401,907 | $2,872,165 |
| Shareholders' Equity | |||||
| Common Shares | 72 | 72 | 72 | 100 | 100 |
| Retained earnings | 2,815,942 | 6,838,357 | 6,789,335 | 7,225,987 | 7,141,819 |
| Other shareholders' equity | 3,030,070 | 2,904,833 | 4,302,895 | 4,945,976 | 6,186,385 |
| TOTAL | $6,396,252 | $10,293,430 | $11,642,470 | $12,712,660 | $13,876,010 |
| Total Liabilities And Equity | $8,541,725 | $12,337,281 | $13,612,015 | $14,114,567 | $16,748,175 |